IMNM

About Immunome, Inc. (IMNM) Stock

Immunome, Inc. (IMNM) closed the 2026-09-18 session at $23.70, down 0.98% versus the previous close (-0.23). The stock opened at $24.01 and traded between $23.36 and $24.08 during that session. Session trading volume was 625K shares. The volume-weighted average price (VWAP) is $23.68.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Immunome, Inc. has a market capitalization of $2.72 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IMNM is listed on the XNAS exchange. The company employs approximately 177 people. Immunome, Inc. is headquartered in BOTHELL, WA. The recorded listing date is 2020-10-02.

On this page you can find market IMNM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.